Effects of hematocrit value on microparticle enzyme immunoassay of tacrolimus concentration in therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 27, Issue 1, 2005, Pages 94-97

  Tomita, Takashi ^a   Homma, Masato ^a,b   Yusawa, Kenji ^b   Ohkohchi, Nobuhiro ^b   Hori, Tetsuo ^b   Kaneko, Michio ^b   Hasegawa, Yuichi ^b   Kojima, Hiroshi ^b   Nagasawa, Toshiro ^b   Kohda, Yukinao ^a,b  

^a UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

False positive concentration; Hematocrit; Microparticle enzyme immunoassay; Tacrolimus; TDM

Indexed keywords

TACROLIMUS;

ADULT; ANEMIA; ARTICLE; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOCRIT; HUMAN; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL; RECIPIENT;

BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HEMATOCRIT; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; PREDICTIVE VALUE OF TESTS; TACROLIMUS; TIME FACTORS;

EID: 19944430748     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200502000-00017     Document Type: Article

References (12)

1. Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta. 2001;313:241-253.
2. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001;34:9-16.
3. Holt DW, Armstrong VW, Griesmacher A, et al. International federation of clinical chemistry/international association of therapeutic drug monitoring and clinical toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002;24:59-67.
4. Staatz CE, Taylor PJ, Tett SE. Comparison of an ELISA and an LC/MS/MS method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients. Ther Drug Monit. 2002;24:607-615.
5. x, Tacrolimus II [package insert]. Abbott Park, IL: Abbott Laboratories, 2003.
6. Tomita T, Homma M, Itagaki F, et al. False positive tacrolimus concentration in microparticle enzyme immunoassay for blood level monitoring. Jpn J Ther Drug Monit. 2003;20:30-34. (in Japanese)
7. Homma M, Tomita T, Yuzawa K, et al. False positive blood tacrolimus concentration in microparticle enzyme immunoassay. Biol Pharm Bull. 2002;25:1119-1120.
8. Kuzuya T, Ogura Y, Motegi Y, et al. Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay. Ther Drug Monit. 2002;24:507-511.
9. Taylor PJ, Morris RG. Tacrolimus measurement by microparticle enzyme immunoassay II. Ther Drug Monit. 2003;25:259-260.
10. Vlahakos DV, Marathias KP, Agroyannis B, et al. Posttransplant erythrocytosis. Kidney Int. 2003;63:1187-1194.
11. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation. 2001;72:449-454.
12. Kleindienst R, Fend F, Prior C, et al. Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis carinii infection in a liver transplant patient receiving tacrolimus. Clin Transplant. 1999;13: 6567.